Core Insights - Entera Bio Ltd. has submitted a clinical amendment to the FDA for EB613, an oral anabolic treatment for osteoporosis, with a streamlined Phase 3 protocol and anticipates feedback within 60 days [1][2][5] - The Phase 3 trial will evaluate the efficacy of EB613 in increasing total hip bone mineral density (BMD) over 12 months, with a target enrollment of 750 postmenopausal women [3][5] - The company expects topline data in the second half of 2028, one year earlier than previously anticipated, and plans to conduct a 12-month open-label extension study in parallel with the NDA review [1][5] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, with EB613 being the first oral anabolic tablet for osteoporosis [9] - The company utilizes a proprietary technology platform (N-Tab) to create innovative oral therapies, aiming to transform the standard of care in various medical fields [9] - Entera's pipeline includes other oral therapies for conditions such as hypoparathyroidism, obesity, and metabolic syndromes, indicating a broad focus on unmet medical needs [9] Industry Context - Osteoporosis is a significant public health issue, leading to over 2 million fractures annually in the US, with a projected increase in medical costs from $57 billion in 2018 to $95 billion by 2040 [8] - The disease predominantly affects postmenopausal women, with one in three women and one in five men likely to suffer an osteoporosis-related fracture after age 50 [8] - Current anabolic therapies for osteoporosis are administered via injection, limiting patient access; Entera's oral formulation aims to democratize treatment and improve patient compliance [6][8]

Group 1 - CVS Health Corporation is recognized as one of the 12 Unstoppable Dividend Stocks to buy according to analysts, with JPMorgan naming it a top pick as its turnaround gains traction [1] - Argus has reduced its price recommendation for CVS from $91 to $90 while maintaining a Buy rating, following a nearly 15% drop in shares after proposed flat Medicare Advantage reimbursement rates for 2027 [1] - The proposed Medicare reimbursement rates are expected to be revised higher before the final decision in April 2026, and CVS's diversified business model is anticipated to cushion the impact better than companies reliant solely on health insurance [1] Group 2 - On February 5, CVS announced changes to its preferred drug lists effective April 1, replacing certain bone disease treatments with lower-cost alternatives through its pharmacy benefit management unit, Caremark [2] - CVS plans to add biosimilar versions of Amgen's Prolia and generic alternatives to Lilly's Forteo across major national commercial formularies [2] - The changes are expected to reduce prescription costs by over 50% compared to branded drugs, with CVS's biosimilar formulary strategy already generating $1.5 billion in gross savings for customers [3] Group 3 - CVS Health Corporation operates as a health solutions company with a diverse range of businesses, including health insurance, pharmacy services, retail pharmacy operations, and related healthcare offerings [3]

Core Viewpoint - CVS Health is enhancing access to lower-cost biosimilar medications, specifically osteoporosis treatments, by introducing new options in its formulary, which will be effective from April 1, 2026, providing significant cost savings compared to original brands [1]. Group 1: Introduction of Biosimilars - CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide options Bonsity and Tymlos, to its major national commercial template formularies [1]. - These biosimilars will replace Prolia and Forteo, offering customers more affordable alternatives with strong clinical and supply confidence [1]. Group 2: Cost Savings and Strategy - The preferred biosimilar approach is over 50% lower in costs per prescription compared to the original brand [1]. - CVS Caremark's biosimilar formulary strategy has already helped customers realize $1.5 billion in gross savings [5]. - The company has successfully transitioned 96% of its client members using Humira to a biosimilar, demonstrating its commitment to driving competition and cost savings [5]. Group 3: Specialty Drug Management - CVS Specialty proactively informs prescribers and patients about formulary changes, ensuring a smooth transition to covered alternatives [6]. - Advanced technology capabilities streamline the prescription process for doctors, allowing for quick approvals and enhancing patient communication [7]. Group 4: Importance of Biosimilars - Biosimilars are crucial for treating complex chronic conditions and are often injectable medications that require careful handling [8]. - The introduction of Ospomyv and Stoboclo is significant for treating osteoporosis, which is vital for preventing fractures and maintaining independence in older adults [9][10]. Group 5: Company Overview - CVS Health operates approximately 9,000 retail pharmacy locations and serves around 87 million plan members through its pharmacy benefits manager [11]. - The company aims to connect consumers to better health through personalized, technology-driven services, ultimately lowering overall healthcare costs [11].

Core Insights - Eli Lilly reported a revenue of $19.29 billion for Q4 2025, marking a year-over-year increase of 42.6% and exceeding the Zacks Consensus Estimate of $17.87 billion by 7.95% [1] - The company's EPS for the same quarter was $7.54, up from $5.32 a year ago, also surpassing the consensus estimate of $6.99 by 7.88% [1] Financial Performance - The stock has returned -5.7% over the past month, while the Zacks S&P 500 composite has increased by 0.9% [3] - Eli Lilly currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Key Product Sales - Jardiance (Empagliflozin/BI 10773) in the US generated $466 million, exceeding the average estimate of $416.12 million, reflecting a year-over-year increase of 0.3% [4] - Jardiance (ROW) reported $302 million, falling short of the $360.06 million estimate, representing a significant year-over-year decline of 58.9% [4] - Cyramza (Ramucirumab/IMC-1121B) in the US achieved $113 million, slightly above the estimate of $111.34 million, with a year-over-year increase of 0.5% [4] - Total sales for Cyramza reached $262 million, surpassing the estimate of $256.17 million, reflecting a year-over-year increase of 1.3% [4] - Humulin sales were $180 million, below the estimate of $204.25 million, indicating a year-over-year decline of 35.8% [4] - Humalog generated $529 million, underperforming the estimate of $570.03 million, with a year-over-year decrease of 14.7% [4] - Forteo sales were $75 million, exceeding the estimate of $55.29 million, marking a year-over-year increase of 21.8% [4] - Erbitux reported $196 million, slightly above the estimate of $192.23 million, with a year-over-year increase of 12% [4] - Alimta sales were $32 million, surpassing the estimate of $28.1 million, but reflecting a year-over-year decline of 17.5% [4] - Other pharmaceuticals generated $192 million, exceeding the estimate of $157.08 million, with a year-over-year increase of 0.7% [4] - Oncology sales totaled $2.61 billion, slightly below the estimate of $2.63 billion, reflecting a year-over-year increase of 2.2% [4]

Core Insights - Analysts project Eli Lilly (LLY) will report quarterly earnings of $6.99 per share, reflecting a 31.4% year-over-year increase, with revenues expected to reach $17.87 billion, a 32.1% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised 8.6% lower over the last 30 days, indicating a reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3] Key Metrics Projections - Analysts expect 'Net Sales- Cyramza' to be $256.17 million, a decrease of 0.9% year-over-year [5] - 'Net Sales- Humulin' is estimated at $204.25 million, reflecting a 27.1% decline [5] - 'Net Sales- Humalog' is projected at $570.03 million, indicating an 8.1% decrease [5] - 'Net Sales- Forteo' is expected to reach $55.29 million, down 10.3% year-over-year [6] - 'Net Sales- Diabetes- Mounjaro - U.S.' is projected at $3.77 billion, a significant increase of 43.1% [6] - Revenue from unaffiliated customers outside the U.S. is expected to be $6.04 billion, up 34.1% [6] - Geographic revenue in the United States is estimated at $11.99 billion, reflecting a 32.8% increase [7] - 'Net Sales- US- Alimta' is projected at $8.62 million, down 31.1% year-over-year [7] - 'Net Sales- US- Forteo' is expected to be $23.94 million, a decrease of 12% [7] - 'Net Sales- US- Humalog' is projected at $353.37 million, indicating a 12.9% decline [8] - 'Net Sales- Humulin- US' is expected to be $127.99 million, down 25.2% [8] - 'Net Sales- International- Alimta' is projected at $19.48 million, reflecting a 26.2% decrease [8] Stock Performance - Over the past month, shares of Lilly have returned -4.7%, while the Zacks S&P 500 composite has increased by 0.9% [9]

Core Insights - Eli Lilly (LLY) is expected to report quarterly earnings of $6.02 per share, reflecting a year-over-year increase of 410.2% [1] - Revenue projections stand at $16.01 billion, indicating a 40% increase from the same quarter last year [1] - The consensus EPS estimate has been adjusted upward by 0.3% over the past 30 days, showing analysts' reassessment of their projections [1][2] Revenue Estimates - Analysts predict 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)' will reach $237.79 million, a year-over-year change of +0.8% [4] - 'Net Sales- Humulin' is estimated at $180.73 million, reflecting a decline of -12.7% year over year [4] - 'Net Sales- Humalog' is projected at $512.59 million, indicating a decrease of -4.1% from the previous year [4] Additional Sales Projections - 'Net Sales- Forteo' is expected to be $96.63 million, down -18.2% year over year [5] - 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- US' is forecasted at $107.96 million, suggesting a +1.4% change year over year [5] - 'Net Sales- International- Humalog' is estimated at $212.55 million, reflecting a +0.8% change from the year-ago quarter [5] Geographic Revenue Insights - 'Net Sales- International- Forteo' is projected at $40.97 million, indicating a -11.7% change year over year [6] - 'Net Sales- Humulin- US' is expected to reach $126.25 million, down -15.8% from the previous year [6] - 'Geographic Revenue- United States' is forecasted to be $11.13 billion, suggesting a +42.5% year-over-year increase [7] Market Performance - Over the past month, Lilly shares have increased by +13.9%, outperforming the Zacks S&P 500 composite's +2.5% change [8] - Based on its Zacks Rank 3 (Hold), LLY is expected to perform in line with the overall market in the upcoming period [8]

Summary of Entera Bio Ltd. Conference Call Company Overview - **Company**: Entera Bio Ltd. - **Industry**: Biopharmaceuticals - **Focus**: Development of first-in-class oral peptide therapies for unmet medical needs - **Ticker Symbol**: ENTX (listed on NASDAQ) - **Cash Runway**: Expected to last until Q3 2026 [2][24] Core Technology and Pipeline - **Technology Platform**: NTAB technology platform enables the development of oral peptide therapies in tablet form, overcoming challenges such as proteolytic degradation and molecular polarity [2][3][4] - **Lead Asset**: EB613, the only oral peptide in development for osteoporosis, is set to enter a phase 3 registrational study [2][4][17] - **Other Pipeline Assets**: Include treatments for hypoparathyroidism, metabolic disorders, obesity, and gastrointestinal inflammation [2][4] EB613 Details - **Mechanism of Action**: EB613 is a PTH(1-34) teriparatide tablet that stimulates bone formation and suppresses bone resorption, aiming to provide a validated mechanism of action in a convenient oral format [6][10][12] - **Clinical Studies**: Phase 2 studies showed favorable outcomes in bone formation markers and bone mineral density (BMD) across skeletal sites [12][13][14] - **Comparison with Forteo**: EB613 has a similar amino acid sequence to Forteo but offers a more rapid onset of action and improved BMD outcomes, particularly at the hip [6][14][15] Osteoporosis Market Insights - **Prevalence**: Approximately 200 million women globally are affected by osteoporosis, with significant fracture risks [7][8] - **Current Treatment Landscape**: Most treatments are antiresorptive drugs, with bisphosphonates being the most commonly prescribed [9][10] - **Patient Access Issues**: Many patients do not receive adequate treatment due to the limitations of injectable therapies and the need for healthcare provider resources [11][19] Phase 3 Study Plans - **Study Design**: A double-blind, placebo-controlled, 24-month study focusing on total hip BMD as the primary endpoint, with secondary endpoints including vertebral fracture trends [17][18] - **Regulatory Alignment**: Recent agreement with the FDA allows the use of total hip BMD as a primary endpoint, a significant milestone for the company [18][23] Market Research and Patient Insights - **Clinician Feedback**: 30% of osteoporosis patients experience suboptimal responses to current treatments, highlighting a need for more effective solutions [19] - **Patient Interest**: 55% of surveyed patients expressed interest in oral bone-building treatments, indicating a potential market for EB613 [19] Future Developments - **Partnership with OPKO Health**: Development of an oral oxyntomodulin tablet is underway, with an IND filing expected in early 2026 [5][20] - **Additional Programs**: Plans to validate a different peptide for hypoparathyroidism and to present supplemental data at upcoming conferences [23] Conclusion - Entera Bio Ltd. is positioned to address significant unmet needs in osteoporosis treatment with its innovative oral peptide therapies, particularly EB613, which aims to enhance patient access and compliance compared to existing injectable options [2][19][24]

Core Viewpoint - Analysts expect Eli Lilly (LLY) to report quarterly earnings of $5.61 per share, reflecting a year-over-year increase of 43.1%, with revenues projected at $14.75 billion, up 30.5% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.5% in the past 30 days, indicating a reassessment by analysts [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' at $246.20 million, a decrease of 1.1% year-over-year [4] - 'Net Sales- Humulin' is expected to be $206.10 million, down 7.8% year-over-year [4] - 'Net Sales- Humalog' is projected at $609.52 million, reflecting a decline of 3.5% from the previous year [4] - 'Net Sales- Forteo' is estimated at $62.76 million, down 10.2% year-over-year [5] - 'Net Sales- International-Forteo' is forecasted at $34.28 million, a decrease of 11% [5] - 'Net Sales- Cyramza (ROW)' is expected to reach $130.32 million, down 1.9% year-over-year [6] - 'Net Sales- Emgality (ROW)' is projected at $42.01 million, indicating a significant decline of 22.8% [6] - 'Net Sales- International-Alimta' is estimated at $17.05 million, down 20.3% from the previous year [6] - 'Net Sales- US-Humulin' is expected to be $154.98 million, down 8.5% year-over-year [7] - 'Net Sales- Emgality (US)' is projected at $135.67 million, reflecting a decrease of 1.4% [7] - 'Net Sales- US-Humalog' is estimated at $412.17 million, down 5.2% year-over-year [7] - 'Net Sales- US-Forteo' is expected to reach $28.73 million, indicating a decline of 8.8% [8] Stock Performance - Over the past month, shares of Lilly have returned -2.4%, contrasting with the Zacks S&P 500 composite's +0.6% change [8]

Core Insights - Eli Lilly reported a revenue of $12.73 billion for the quarter ended March 2025, marking a 45.2% increase year-over-year, with an EPS of $3.34 compared to $2.58 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $12.62 billion by 0.86%, while the EPS fell short of the consensus estimate of $3.52 by 5.11% [1] Financial Performance - Key metrics indicate that Eli Lilly's shares have returned +9.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Sales Breakdown - Verzenio in the U.S. generated net sales of $657.60 million, below the average estimate of $720.57 million, reflecting a year-over-year increase of 3% [4] - Neuroscience products in the U.S. achieved net sales of $189.30 million, slightly above the average estimate of $188.66 million, with a year-over-year growth of 16% [4] - Geographic revenue from the U.S. reached $8.49 billion, slightly below the $8.50 billion estimate, representing a 49.1% year-over-year increase [4] - Humalog's net sales were $335.10 million, below the average estimate of $361.22 million, showing a year-over-year decline of 1% [4] - Cyramza's total net sales were $224.90 million, slightly below the estimate of $227.45 million, with a year-over-year decrease of 2.2% [4] - Humulin's net sales were $173.20 million, significantly below the estimate of $203.01 million, reflecting a 16% year-over-year decline [4] - Forteo's net sales were $66.60 million, exceeding the average estimate of $50.84 million, with an 8.7% year-over-year increase [4] - Erbitux's net sales were $149 million, slightly above the estimate of $146.04 million, indicating a 3% year-over-year increase [4] - Alimta's net sales were $28.20 million, significantly below the estimate of $46.13 million, showing a 59.4% year-over-year decline [4] - Other pharmaceuticals generated net sales of $212.90 million, slightly below the estimate of $213.18 million, reflecting a 12% year-over-year decline [4] - Oncology products achieved net sales of $1.95 billion, below the average estimate of $2.07 billion, with a year-over-year increase of 7.6% [4]

Core Viewpoint - Eli Lilly and Company is set to report its first-quarter earnings on May 1, with sales and earnings estimates at $12.62 billion and $3.52 per share, respectively. However, earnings estimates for 2025 have seen a decline from $23.53 to $22.43 per share over the past month [1][4]. Earnings Performance - The company has had a mixed earnings performance, exceeding expectations in three of the last four quarters, with an average earnings surprise of 8.47% [2][3]. Earnings Estimates and Trends - Current earnings estimates for Q1, Q2, 2025, and 2026 are $3.52, $5.58, $22.43, and $31.15 per share, respectively. Notably, the earnings estimate for Q1 has decreased by 22.30% over the past month [1][4]. Factors Influencing Upcoming Results - Top-line growth in Q1 is expected to be driven by demand for FDA-approved tirzepatide medicines, specifically the diabetes drug Mounjaro and weight loss medicine Zepbound. However, sales of these drugs were below expectations in the latter half of 2024 due to slower growth and unfavorable channel dynamics [5][6]. Sales Estimates for Key Products - The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion, respectively, while the company's estimates are $3.82 billion and $2.19 billion. Increased demand for other key growth drugs is also anticipated to support top-line growth [8][10]. Competitive Landscape - Sales of Trulicity are expected to decline due to competitive dynamics and lower realized prices in the U.S., with patient switches to Mounjaro impacting its performance [9][22]. The obesity market is becoming increasingly competitive, with several companies developing GLP-1-based candidates [23][24]. Stock Performance and Valuation - Lilly's stock has risen 14.8% year-to-date, outperforming the industry and the S&P 500 index. The stock is currently trading at a premium compared to the industry [13][16]. Investment Outlook - Despite challenges, including declining sales of key products and increasing competition, the company is viewed as having robust growth prospects, particularly with new product launches and expansions planned for 2025 [20][25].